FDA issues warning over Philips fetal monitors

Justine Varieur Cadet | | Health Imaging | Screening
The FDA has issued a letter to notify healthcare professionals and facilities of a number of complaints of inaccurate readings when using the Philips Healthcare Avalon fetal monitors, models FM20, FM30, FM40, and FM50 with the ultrasound transducer to measure fetal heart rate.

On Sept. 4, Philips issued an important device safety alert. Inaccurate output readings, if not properly addressed, may lead to unnecessary interventions, failure to identify the need for interventions and failure to identify fetal distress, according to the company.

The complaints most commonly occur during the second stage of labor, the agency reported. Philips received a number of complaints of inaccurate output readings that prompted this alert.

Justine Varieur Cadet

Related Content

Rising rates of interval breast cancers have experts calling for more risk-based screenings
Rates of breast cancer diagnosis, death expected to climb in coming decades
AI quantifies breast arterial calcifications on mammograms
AI 'not safe' to be implemented as a solo reader for breast cancer screening exams
American College of Radiology announces significant expansion of Lung Cancer Screening Registry
AI beats standard regression models at predicting lung cancer risk

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.